--
Advanced OLINVYK commercial launch with expanded field medical team and additional target markets
Announced new OLINVYK cognitive function study vs. IV morphine, enrollment expected to start in Q1 2022
Read more at globenewswire.comProvided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.